Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
Authors:
- Jenny L. DonovanJDJenny L. Donovan
- Freddie C. HamdyFHFreddie C. Hamdy
- J. Athene LaneJLJ. Athene Lane
- Malcolm MasonMMMalcolm Mason
- Chris MetcalfeCMChris Metcalfe
- Eleanor WalshEWEleanor Walsh
- Jane M. BlazebyJBJane M. Blazeby
- Tim J. PetersTPTim J. Peters
- Peter HoldingPHPeter Holding
- Susan BonningtonSBSusan Bonnington
- Teresa LennonTLTeresa Lennon
- Lynne BradshawLBLynne Bradshaw
Top Cited Papers
- 13 October 2016
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (15) , 1425-1437
Abstract
Robust data on patient-reported outcome measures comparing treatments for clinically localized prostate cancer are lacking. We investigated the effects of active monitoring, radical prostatectomy, and radical radiotherapy with hormones on patient-reported outcomes. We compared patient-reported outcomes among 1643 men in the Prostate Testing for Cancer and Treatment (ProtecT) trial who completed questionnaires before diagnosis, at 6 and 12 months after randomization, and annually thereafter. Patients completed validated measures that assessed urinary, bowel, and sexual function and specific effects on quality of life, anxiety and depression, and general health. Cancer-related quality of life was assessed at 5 years. Complete 6-year data were analyzed according to the intention-to-treat principle. The rate of questionnaire completion during follow-up was higher than 85% for most measures. Of the three treatments, prostatectomy had the greatest negative effect on sexual function and urinary continence, and although there was some recovery, these outcomes remained worse in the prostatectomy group than in the other groups throughout the trial. The negative effect of radiotherapy on sexual function was greatest at 6 months, but sexual function then recovered somewhat and was stable thereafter; radiotherapy had little effect on urinary continence. Sexual and urinary function declined gradually in the active-monitoring group. Bowel function was worse in the radiotherapy group at 6 months than in the other groups but then recovered somewhat, except for the increasing frequency of bloody stools; bowel function was unchanged in the other groups. Urinary voiding and nocturia were worse in the radiotherapy group at 6 months but then mostly recovered and were similar to the other groups after 12 months. Effects on quality of life mirrored the reported changes in function. No significant differences were observed among the groups in measures of anxiety, depression, or general health-related or cancer-related quality of life. In this analysis of patient-reported outcomes after treatment for localized prostate cancer, patterns of severity, recovery, and decline in urinary, bowel, and sexual function and associated quality of life differed among the three groups. (Funded by the U.K. National Institute for Health Research Health Technology Assessment Program; ProtecT Current Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.)Keywords
This publication has 40 references indexed in Scilit:
- Radical Prostatectomy versus Observation for Localized Prostate CancerNew England Journal of Medicine, 2012
- Adverse Effects of Robotic-Assisted Laparoscopic Versus Open Retropubic Radical Prostatectomy Among a Nationwide Random Sample of Medicare-Age MenJournal of Clinical Oncology, 2012
- Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2011
- A Peer Review Intervention for Monitoring and Evaluating sites (PRIME) that improved randomized controlled trial conduct and performanceJournal of Clinical Epidemiology, 2011
- Prostate‐specific antigen testing rates remain low in UK general practice: a cross‐sectional study in six English citiesBJU International, 2011
- Mortality Results from a Randomized Prostate-Cancer Screening TrialNew England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- ICIQ: A brief and robust measure for evaluating the symptoms and impact of urinary incontinenceNeurourology and Urodynamics, 2004
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983